CASGEVY is a one-time therapy used to treat people aged 12 years and older with: sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs. beta thalassemia (β-thalassemia) who need regular blood transfusions

Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [3] [5] and transfusion-dependent beta thalassemia. [3] It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics. [9]

Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first...

Jan 17, 2024 · Casgevy (exagamglogene autotemcel) is a gene therapy that is given as a one-time intravenous infusion to treat adults and children aged 12 years and older with: Sickle cell disease with recurrent vaso-occlusive crises (VOCs). …

CASGEVY indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs).

Dec 15, 2023 · Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older. For beta thalassaemia, Casgevy is used in patients who require regular blood transfusions.

CASGEVY is indicated for the treatment of patients aged 12 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) transfusion-dependent β-thalassemia (TDT)

CASGEVY is a one-time* gene therapy that may help people 12 years and older with sickle cell disease (SCD) and frequent vaso-occlusive crises (VOCs) live severe VOC-free. CASGEVY uses your own blood stem cells to help your body make working red …

Sep 14, 2024 · CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy indicated for the treatment of patients aged 12 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). ( 1) transfusion-dependent β-thalassemia (TDT). ( 1) For autologous use only. For intravenous use only.

Jan 18, 2024 · Exa-cel, also known by its brand name Casgevy, received its first regulatory approval on Nov. 16, 2023 from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat two...